These findings raise the novel hypothesis that SLC6A20 variants contribute to variation in COVID-19 outcomes due to differences in expression or protein function related to interactions with ACE2, the SARS-CoV-2 receptor. This evidence concerns the gene ACE2 and COVID-19.